Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023)

Table 1 Reported clinical results of neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma

Ref.	Year	Title	LCS	GCS
Musso et al[93]	2010	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease	213	410
Sanyal et al[30]	2010	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis	986	2063
Promrat et al[35]	2010	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis	426	832
Ratziu et al[22]	2010	A position statement on NAFLD/NASH based on the EASL 2009 special conference	245	731
Lavine et al[94]	2011	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the toninc randomized controlled trial	363	711
Musso et al[105]	2012	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomised trials	224	435
Mudaliar et al[96]	2013	Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease	234	631
Neuschwander-Tetri et al[31]	2015	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial	586	1416
Rinella et al[32]	2015	Nonalcoholic fatty liver disease: A systematic review	403	1443
Buzzetti et al[97]	2016	The multiple-hit pathogenesis of NAFLD	538	1386
Boursier et al[98]	2016	The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota	213	717
Cusi et al[106]	2016	Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial	277	525
Ratziu et al[107]	2016	Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening	350	642
Armstrong et al[36]	2016	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study	529	1006
Friedman et al[37]	2018	Mechanisms of NAFLD development and therapeutic strategies	550	1526
Younossi et al[33]	2018	Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention	739	2379
Younossi[56]	2019	Non-alcoholic fatty liver disease-a global public health perspective	243	906
Younossi et al[6]	2019	Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	254	808
Younossi et al[34]	2019	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial	263	541

EASL: European association for the study of the liver; GCS: Global cited documents; LCS: Local cited documents; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.